Danske Bank A S Lowers Stock Holdings in Becton, Dickinson and Company $BDX

Danske Bank A S lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 17.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 228,234 shares of the medical instruments supplier’s stock after selling 47,003 shares during the quarter. Danske Bank A S’s holdings in Becton, Dickinson and Company were worth $34,539,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Imprint Wealth LLC acquired a new position in Becton, Dickinson and Company in the 3rd quarter valued at about $25,000. SHP Wealth Management purchased a new stake in Becton, Dickinson and Company during the fourth quarter worth about $26,000. Meeder Asset Management Inc. lifted its position in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares in the last quarter. Main Street Group LTD purchased a new position in shares of Becton, Dickinson and Company in the first quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc purchased a new position in shares of Becton, Dickinson and Company in the second quarter valued at approximately $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $187.82 on Thursday. The firm has a market capitalization of $51.75 billion, a price-to-earnings ratio of 56.57, a PEG ratio of 12.74 and a beta of 0.19. The firm’s fifty day simple moving average is $159.86 and its 200-day simple moving average is $161.02. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.96. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the firm posted $3.68 earnings per share. The company’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 11,779 shares of company stock valued at $1,974,669 over the last three months. 0.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

BDX has been the topic of several recent research reports. The Goldman Sachs Group cut their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Jefferies Financial Group restated a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a research report on Friday, August 7th. Royal Bank Of Canada increased their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Finally, Barclays boosted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.